AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|
12.3 C
New York
Sunday, November 22, 2026

Tag: BIO MTC HEA

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

HANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on integrated...

Myosin Therapeutics to Attend Society for Neuro-Oncology 2026 Annual Meeting

JUPITER, Fla., Nov. 9, 2026 /PRNewswire/ -- Myosin Therapeutics today announced that Dr. Courtney Miller (CEO) and Dr. Karen Smith (CMO) will attend the...

Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

SINTBILO®  (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg...

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance...

HOUSTON, Nov. 5, 2026 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and...

ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance...

HOUSTON, Nov. 5, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and...

Verismo Therapeutics to Present First-in-Human SynKIR™-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and Favorable Safety Profile in Oral Presentation at 68th ASH Annual...

Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with...

SOTERIA Precision Medicine Foundation Launches Cancer Hunt™ to Provide Advanced Precision Oncology Support Services for Active-Duty U.S. Military and Veterans

A groundbreaking national initiative delivering comprehensive genomic profiling, biomarker interpretation, and dedicated nurse navigation to support active-duty and veteran military patients with cancer. SAN...

Myosin Therapeutics Invited to Present at BioFuture 2026 in New York City

JUPITER, Fla., Oct. 16, 2026 /PRNewswire/ -- Myosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives...

Perceptive Discovery Launches Astatine-211 Study Capabilities in the US and UK

Perceptive Discovery becomes the first US provider able to support At-211 studies, expanding access to specialized radiopharmaceutical development infrastructure through its collaboration with Atley...

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett’s Esophagus

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/...

Resolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren’s Disease

Approximately 110 participants enrolled in randomized, double-blind, placebo-controlled study; topline results expected in the second quarter of 2027MIAMI, Oct. 7, 2026 /PRNewswire/ -- Resolve...

Taiwan Biotech Delegation Showcases Regional Innovation in CDMO, Cell Therapy, and Biologics at BioJapan 2026

YOKOHAMA, Japan, Oct. 6, 2026 /PRNewswire/ -- Highlighting regional life sciences innovation, 17 Taiwanese biotech companies and research institutions are gathering at BioJapan 2026 (Oct....

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBIO MTC HEA